Navigation Menu


Autobahn Therapeutics to Participate in Upcoming Investor Conferences


SAN DIEGO – Feb. 22, 2024 – Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in two upcoming investor conferences:


Evercore ISI’s 2024 Emerging Private Biotech Conference

Company Presentation: Thursday, February 29, 2024, at 1:05 p.m. ET

Location: Virtual


TD Cowen’s 44th Annual Health Care Conference

Investor Meetings: Wednesday, March 6, 2024

Location: Marriott Copley Place, Boston, MA



About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit




Bill Slattery, Jr.

THRUST Strategic Communications